I-Mab
I-Mab (IMAB) Stock Competitors & Peer Comparison
See (IMAB) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IMAB | $2.88 | -0.69% | 542M | -5.65 | -$0.51 | N/A |
| NVO | $45.12 | +1.89% | 196.8B | 10.30 | $4.30 | +4.05% |
| VRTX | $429.17 | -1.70% | 110.3B | 25.79 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $647.56 | +2.84% | 64.9B | 15.38 | $40.99 | +0.57% |
| ARGX | $800.38 | +3.11% | 49.4B | 35.41 | $22.54 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $294.36 | +2.83% | 39.3B | 73.76 | $3.99 | N/A |
| RVMD | $148.77 | +3.05% | 31.3B | -20.72 | -$7.11 | N/A |
| UTHR | $566.27 | -0.13% | 24.1B | 20.95 | $27.06 | N/A |
Stock Comparison
IMAB vs NVO Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, NVO has a market cap of 196.8B. Regarding current trading prices, IMAB is priced at $2.88, while NVO trades at $45.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas NVO's P/E ratio is 10.30. In terms of profitability, IMAB's ROE is -0.09%, compared to NVO's ROE of +0.66%. Regarding short-term risk, IMAB is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check NVO's competition here
IMAB vs VRTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, VRTX has a market cap of 110.3B. Regarding current trading prices, IMAB is priced at $2.88, while VRTX trades at $429.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas VRTX's P/E ratio is 25.79. In terms of profitability, IMAB's ROE is -0.09%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, IMAB is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check VRTX's competition here
IMAB vs VRNA Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IMAB is priced at $2.88, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IMAB's ROE is -0.09%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, IMAB is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check VRNA's competition here
IMAB vs REGN Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, REGN has a market cap of 64.9B. Regarding current trading prices, IMAB is priced at $2.88, while REGN trades at $647.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas REGN's P/E ratio is 15.38. In terms of profitability, IMAB's ROE is -0.09%, compared to REGN's ROE of +0.14%. Regarding short-term risk, IMAB is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check REGN's competition here
IMAB vs ARGX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ARGX has a market cap of 49.4B. Regarding current trading prices, IMAB is priced at $2.88, while ARGX trades at $800.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ARGX's P/E ratio is 35.41. In terms of profitability, IMAB's ROE is -0.09%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, IMAB is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ARGX's competition here
IMAB vs SGEN Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IMAB is priced at $2.88, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IMAB's ROE is -0.09%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IMAB is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check SGEN's competition here
IMAB vs ALNY Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ALNY has a market cap of 39.3B. Regarding current trading prices, IMAB is priced at $2.88, while ALNY trades at $294.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ALNY's P/E ratio is 73.76. In terms of profitability, IMAB's ROE is -0.09%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, IMAB is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ALNY's competition here
IMAB vs RVMD Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, RVMD has a market cap of 31.3B. Regarding current trading prices, IMAB is priced at $2.88, while RVMD trades at $148.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas RVMD's P/E ratio is -20.72. In terms of profitability, IMAB's ROE is -0.09%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, IMAB is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RVMD's competition here
IMAB vs UTHR Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, UTHR has a market cap of 24.1B. Regarding current trading prices, IMAB is priced at $2.88, while UTHR trades at $566.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas UTHR's P/E ratio is 20.95. In terms of profitability, IMAB's ROE is -0.09%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IMAB is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check UTHR's competition here
IMAB vs INSM Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, INSM has a market cap of 23.3B. Regarding current trading prices, IMAB is priced at $2.88, while INSM trades at $107.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas INSM's P/E ratio is -18.65. In terms of profitability, IMAB's ROE is -0.09%, compared to INSM's ROE of -1.30%. Regarding short-term risk, IMAB is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check INSM's competition here
IMAB vs RPRX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, RPRX has a market cap of 22.5B. Regarding current trading prices, IMAB is priced at $2.88, while RPRX trades at $53.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas RPRX's P/E ratio is 27.58. In terms of profitability, IMAB's ROE is -0.09%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, IMAB is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RPRX's competition here
IMAB vs BNTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, BNTX has a market cap of 22.2B. Regarding current trading prices, IMAB is priced at $2.88, while BNTX trades at $90.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas BNTX's P/E ratio is -14.78. In terms of profitability, IMAB's ROE is -0.09%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, IMAB is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BNTX's competition here
IMAB vs BGNE Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IMAB is priced at $2.88, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IMAB's ROE is -0.09%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, IMAB is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BGNE's competition here
IMAB vs ROIV Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ROIV has a market cap of 20.2B. Regarding current trading prices, IMAB is priced at $2.88, while ROIV trades at $32.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ROIV's P/E ratio is -24.11. In terms of profitability, IMAB's ROE is -0.09%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, IMAB is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check ROIV's competition here
IMAB vs INCY Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, IMAB is priced at $2.88, while INCY trades at $96.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas INCY's P/E ratio is 13.50. In terms of profitability, IMAB's ROE is -0.09%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IMAB is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check INCY's competition here
IMAB vs DNA-WT Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IMAB is priced at $2.88, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IMAB's ROE is -0.09%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, IMAB is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check DNA-WT's competition here
IMAB vs MRNA Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, MRNA has a market cap of 18.1B. Regarding current trading prices, IMAB is priced at $2.88, while MRNA trades at $48.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas MRNA's P/E ratio is -5.62. In terms of profitability, IMAB's ROE is -0.09%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, IMAB is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MRNA's competition here
IMAB vs GMAB Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, GMAB has a market cap of 15.8B. Regarding current trading prices, IMAB is priced at $2.88, while GMAB trades at $27.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas GMAB's P/E ratio is 19.45. In terms of profitability, IMAB's ROE is -0.09%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, IMAB is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check GMAB's competition here
IMAB vs NBIX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, NBIX has a market cap of 15.5B. Regarding current trading prices, IMAB is priced at $2.88, while NBIX trades at $154.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas NBIX's P/E ratio is 23.75. In terms of profitability, IMAB's ROE is -0.09%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, IMAB is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check NBIX's competition here
IMAB vs JAZZ Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, JAZZ has a market cap of 14.9B. Regarding current trading prices, IMAB is priced at $2.88, while JAZZ trades at $240.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas JAZZ's P/E ratio is 2158.64. In terms of profitability, IMAB's ROE is -0.09%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, IMAB is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check JAZZ's competition here
IMAB vs ASND Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, IMAB is priced at $2.88, while ASND trades at $239.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ASND's P/E ratio is 26.85. In terms of profitability, IMAB's ROE is -0.09%, compared to ASND's ROE of -56.42%. Regarding short-term risk, IMAB is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ASND's competition here
IMAB vs BBIO Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, BBIO has a market cap of 12.9B. Regarding current trading prices, IMAB is priced at $2.88, while BBIO trades at $68.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas BBIO's P/E ratio is -17.65. In terms of profitability, IMAB's ROE is -0.09%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, IMAB is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BBIO's competition here
IMAB vs KRTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IMAB is priced at $2.88, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IMAB's ROE is -0.09%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IMAB is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check KRTX's competition here
IMAB vs SMMT Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, SMMT has a market cap of 12.3B. Regarding current trading prices, IMAB is priced at $2.88, while SMMT trades at $17.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas SMMT's P/E ratio is -9.97. In terms of profitability, IMAB's ROE is -0.09%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, IMAB is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check SMMT's competition here
IMAB vs EXEL Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, EXEL has a market cap of 12.2B. Regarding current trading prices, IMAB is priced at $2.88, while EXEL trades at $49.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas EXEL's P/E ratio is 16.12. In terms of profitability, IMAB's ROE is -0.09%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, IMAB is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check EXEL's competition here
IMAB vs IONS Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, IMAB is priced at $2.88, while IONS trades at $75.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas IONS's P/E ratio is -36.74. In terms of profitability, IMAB's ROE is -0.09%, compared to IONS's ROE of -0.59%. Regarding short-term risk, IMAB is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check IONS's competition here
IMAB vs MDGL Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, IMAB is priced at $2.88, while MDGL trades at $518.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas MDGL's P/E ratio is -37.88. In terms of profitability, IMAB's ROE is -0.09%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, IMAB is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MDGL's competition here
IMAB vs AXSM Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, AXSM has a market cap of 11.7B. Regarding current trading prices, IMAB is priced at $2.88, while AXSM trades at $229.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas AXSM's P/E ratio is -61.10. In terms of profitability, IMAB's ROE is -0.09%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, IMAB is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check AXSM's competition here
IMAB vs RNAM Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IMAB is priced at $2.88, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IMAB's ROE is -0.09%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IMAB is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RNAM's competition here
IMAB vs ARWR Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ARWR has a market cap of 10.3B. Regarding current trading prices, IMAB is priced at $2.88, while ARWR trades at $76.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ARWR's P/E ratio is -32.23. In terms of profitability, IMAB's ROE is -0.09%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, IMAB is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ARWR's competition here
IMAB vs BMRN Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, BMRN has a market cap of 9.6B. Regarding current trading prices, IMAB is priced at $2.88, while BMRN trades at $50.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas BMRN's P/E ratio is 35.82. In terms of profitability, IMAB's ROE is -0.09%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, IMAB is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BMRN's competition here
IMAB vs RXDX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IMAB is priced at $2.88, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IMAB's ROE is -0.09%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RXDX's competition here
IMAB vs CYTK Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CYTK has a market cap of 9.5B. Regarding current trading prices, IMAB is priced at $2.88, while CYTK trades at $78.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CYTK's P/E ratio is -11.16. In terms of profitability, IMAB's ROE is -0.09%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, IMAB is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CYTK's competition here
IMAB vs IMGN Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IMAB is priced at $2.88, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IMAB's ROE is -0.09%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IMAB is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check IMGN's competition here
IMAB vs KRYS Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, KRYS has a market cap of 8.7B. Regarding current trading prices, IMAB is priced at $2.88, while KRYS trades at $299.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas KRYS's P/E ratio is 39.29. In terms of profitability, IMAB's ROE is -0.09%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IMAB is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check KRYS's competition here
IMAB vs BPMC Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IMAB is priced at $2.88, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IMAB's ROE is -0.09%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, IMAB is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BPMC's competition here
IMAB vs CERE Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IMAB is priced at $2.88, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CERE's P/E ratio is -16.47. In terms of profitability, IMAB's ROE is -0.09%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IMAB is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CERE's competition here
IMAB vs HALO Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, IMAB is priced at $2.88, while HALO trades at $68.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas HALO's P/E ratio is 24.12. In terms of profitability, IMAB's ROE is -0.09%, compared to HALO's ROE of +1.26%. Regarding short-term risk, IMAB is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check HALO's competition here
IMAB vs IBRX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, IBRX has a market cap of 8.1B. Regarding current trading prices, IMAB is priced at $2.88, while IBRX trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas IBRX's P/E ratio is -9.13. In terms of profitability, IMAB's ROE is -0.09%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, IMAB is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check IBRX's competition here
IMAB vs ABVX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ABVX has a market cap of 7.4B. Regarding current trading prices, IMAB is priced at $2.88, while ABVX trades at $119.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ABVX's P/E ratio is -20.07. In terms of profitability, IMAB's ROE is -0.09%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, IMAB is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ABVX's competition here
IMAB vs NUVL Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, NUVL has a market cap of 7.4B. Regarding current trading prices, IMAB is priced at $2.88, while NUVL trades at $102.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas NUVL's P/E ratio is -16.67. In terms of profitability, IMAB's ROE is -0.09%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IMAB is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check NUVL's competition here
IMAB vs MTSR Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IMAB is priced at $2.88, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IMAB's ROE is -0.09%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, IMAB is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MTSR's competition here
IMAB vs TECH Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, TECH has a market cap of 7.1B. Regarding current trading prices, IMAB is priced at $2.88, while TECH trades at $46.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas TECH's P/E ratio is 64.96. In terms of profitability, IMAB's ROE is -0.09%, compared to TECH's ROE of +0.05%. Regarding short-term risk, IMAB is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check TECH's competition here
IMAB vs PCVX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, PCVX has a market cap of 7B. Regarding current trading prices, IMAB is priced at $2.88, while PCVX trades at $46.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas PCVX's P/E ratio is -7.08. In terms of profitability, IMAB's ROE is -0.09%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, IMAB is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check PCVX's competition here
IMAB vs MRUS Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IMAB is priced at $2.88, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IMAB's ROE is -0.09%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, IMAB is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MRUS's competition here
IMAB vs PRAX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, IMAB is priced at $2.88, while PRAX trades at $334.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas PRAX's P/E ratio is -23.93. In terms of profitability, IMAB's ROE is -0.09%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, IMAB is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check PRAX's competition here
IMAB vs ACLX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IMAB is priced at $2.88, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IMAB's ROE is -0.09%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IMAB is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ACLX's competition here
IMAB vs RETA Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IMAB is priced at $2.88, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas RETA's P/E ratio is -66.29. In terms of profitability, IMAB's ROE is -0.09%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IMAB is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RETA's competition here
IMAB vs KYMR Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, KYMR has a market cap of 6.4B. Regarding current trading prices, IMAB is priced at $2.88, while KYMR trades at $80.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas KYMR's P/E ratio is -21.83. In terms of profitability, IMAB's ROE is -0.09%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, IMAB is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check KYMR's competition here
IMAB vs CELC Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CELC has a market cap of 6.4B. Regarding current trading prices, IMAB is priced at $2.88, while CELC trades at $140.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CELC's P/E ratio is -33.61. In terms of profitability, IMAB's ROE is -0.09%, compared to CELC's ROE of -2.45%. Regarding short-term risk, IMAB is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check CELC's competition here
IMAB vs PTGX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, PTGX has a market cap of 6.3B. Regarding current trading prices, IMAB is priced at $2.88, while PTGX trades at $100.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas PTGX's P/E ratio is -54.35. In terms of profitability, IMAB's ROE is -0.09%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, IMAB is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check PTGX's competition here
IMAB vs CORT Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CORT has a market cap of 6.3B. Regarding current trading prices, IMAB is priced at $2.88, while CORT trades at $58.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CORT's P/E ratio is 171.24. In terms of profitability, IMAB's ROE is -0.09%, compared to CORT's ROE of +0.08%. Regarding short-term risk, IMAB is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CORT's competition here
IMAB vs ALKS Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ALKS has a market cap of 6.2B. Regarding current trading prices, IMAB is priced at $2.88, while ALKS trades at $37.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ALKS's P/E ratio is 41.11. In terms of profitability, IMAB's ROE is -0.09%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, IMAB is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ALKS's competition here
IMAB vs CNTA Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, IMAB is priced at $2.88, while CNTA trades at $39.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CNTA's P/E ratio is -22.30. In terms of profitability, IMAB's ROE is -0.09%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IMAB is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CNTA's competition here
IMAB vs TGTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, TGTX has a market cap of 6B. Regarding current trading prices, IMAB is priced at $2.88, while TGTX trades at $39.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas TGTX's P/E ratio is 13.79. In terms of profitability, IMAB's ROE is -0.09%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, IMAB is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check TGTX's competition here
IMAB vs RYTM Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, IMAB is priced at $2.88, while RYTM trades at $89.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas RYTM's P/E ratio is -27.84. In terms of profitability, IMAB's ROE is -0.09%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, IMAB is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RYTM's competition here
IMAB vs PTCT Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, IMAB is priced at $2.88, while PTCT trades at $71.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas PTCT's P/E ratio is -27.68. In terms of profitability, IMAB's ROE is -0.09%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, IMAB is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check PTCT's competition here
IMAB vs SRRK Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, IMAB is priced at $2.88, while SRRK trades at $48.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas SRRK's P/E ratio is -13.79. In terms of profitability, IMAB's ROE is -0.09%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, IMAB is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check SRRK's competition here
IMAB vs CDTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IMAB is priced at $2.88, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IMAB's ROE is -0.09%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, IMAB is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CDTX's competition here
IMAB vs CGON Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, IMAB is priced at $2.88, while CGON trades at $64.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CGON's P/E ratio is -27.05. In terms of profitability, IMAB's ROE is -0.09%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IMAB is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CGON's competition here
IMAB vs BLTE Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, BLTE has a market cap of 5.6B. Regarding current trading prices, IMAB is priced at $2.88, while BLTE trades at $142.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas BLTE's P/E ratio is -60.48. In terms of profitability, IMAB's ROE is -0.09%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, IMAB is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check BLTE's competition here
IMAB vs ABCM Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IMAB is priced at $2.88, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IMAB's ROE is -0.09%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IMAB is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ABCM's competition here
IMAB vs ISEE Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IMAB is priced at $2.88, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IMAB's ROE is -0.09%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IMAB is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ISEE's competition here
IMAB vs IMVT Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, IMVT has a market cap of 5.4B. Regarding current trading prices, IMAB is priced at $2.88, while IMVT trades at $35.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas IMVT's P/E ratio is -9.85. In terms of profitability, IMAB's ROE is -0.09%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, IMAB is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check IMVT's competition here
IMAB vs COGT Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, IMAB is priced at $2.88, while COGT trades at $33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas COGT's P/E ratio is -14.40. In terms of profitability, IMAB's ROE is -0.09%, compared to COGT's ROE of -0.83%. Regarding short-term risk, IMAB is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check COGT's competition here
IMAB vs LQDA Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, LQDA has a market cap of 5.3B. Regarding current trading prices, IMAB is priced at $2.88, while LQDA trades at $61.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas LQDA's P/E ratio is 352.82. In terms of profitability, IMAB's ROE is -0.09%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, IMAB is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check LQDA's competition here
IMAB vs APLS Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IMAB is priced at $2.88, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas APLS's P/E ratio is 38.35. In terms of profitability, IMAB's ROE is -0.09%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IMAB is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check APLS's competition here
IMAB vs FBIOX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, FBIOX has a market cap of 5B. Regarding current trading prices, IMAB is priced at $2.88, while FBIOX trades at $24.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas FBIOX's P/E ratio is N/A. In terms of profitability, IMAB's ROE is -0.09%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, IMAB is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check FBIOX's competition here
IMAB vs LEGN Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, LEGN has a market cap of 5B. Regarding current trading prices, IMAB is priced at $2.88, while LEGN trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas LEGN's P/E ratio is -19.52. In terms of profitability, IMAB's ROE is -0.09%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, IMAB is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check LEGN's competition here
IMAB vs APGE Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, APGE has a market cap of 4.8B. Regarding current trading prices, IMAB is priced at $2.88, while APGE trades at $80.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas APGE's P/E ratio is -18.11. In terms of profitability, IMAB's ROE is -0.09%, compared to APGE's ROE of -0.33%. Regarding short-term risk, IMAB is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check APGE's competition here
IMAB vs MIRM Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, IMAB is priced at $2.88, while MIRM trades at $96.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas MIRM's P/E ratio is -7.03. In terms of profitability, IMAB's ROE is -0.09%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, IMAB is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MIRM's competition here
IMAB vs TERN Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, IMAB is priced at $2.88, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas TERN's P/E ratio is -51.41. In terms of profitability, IMAB's ROE is -0.09%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IMAB is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check TERN's competition here
IMAB vs CRSP Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, IMAB is priced at $2.88, while CRSP trades at $48.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CRSP's P/E ratio is -7.71. In terms of profitability, IMAB's ROE is -0.09%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CRSP's competition here
IMAB vs FOLD Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IMAB is priced at $2.88, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IMAB's ROE is -0.09%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IMAB is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check FOLD's competition here
IMAB vs AKRO Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IMAB is priced at $2.88, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IMAB's ROE is -0.09%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check AKRO's competition here
IMAB vs ALPN Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IMAB is priced at $2.88, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IMAB's ROE is -0.09%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IMAB is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ALPN's competition here
IMAB vs XENE Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, IMAB is priced at $2.88, while XENE trades at $54.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas XENE's P/E ratio is -11.50. In terms of profitability, IMAB's ROE is -0.09%, compared to XENE's ROE of -0.49%. Regarding short-term risk, IMAB is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check XENE's competition here
IMAB vs OPT Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IMAB is priced at $2.88, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas OPT's P/E ratio is -1.52. In terms of profitability, IMAB's ROE is -0.09%, compared to OPT's ROE of +0.88%. Regarding short-term risk, IMAB is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check OPT's competition here
IMAB vs CAI Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CAI has a market cap of 4.2B. Regarding current trading prices, IMAB is priced at $2.88, while CAI trades at $15.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CAI's P/E ratio is -5.42. In terms of profitability, IMAB's ROE is -0.09%, compared to CAI's ROE of +0.06%. Regarding short-term risk, IMAB is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check CAI's competition here
IMAB vs MANE Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, IMAB is priced at $2.88, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas MANE's P/E ratio is -37.73. In terms of profitability, IMAB's ROE is -0.09%, compared to MANE's ROE of -0.95%. Regarding short-term risk, IMAB is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MANE's competition here
IMAB vs LGND Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, LGND has a market cap of 4.2B. Regarding current trading prices, IMAB is priced at $2.88, while LGND trades at $219.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas LGND's P/E ratio is 27.09. In terms of profitability, IMAB's ROE is -0.09%, compared to LGND's ROE of +0.16%. Regarding short-term risk, IMAB is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check LGND's competition here
IMAB vs MRTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IMAB is priced at $2.88, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IMAB's ROE is -0.09%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IMAB is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MRTX's competition here
IMAB vs SYRE Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, SYRE has a market cap of 4B. Regarding current trading prices, IMAB is priced at $2.88, while SYRE trades at $71.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas SYRE's P/E ratio is -31.42. In terms of profitability, IMAB's ROE is -0.09%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check SYRE's competition here
IMAB vs KNSA Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, KNSA has a market cap of 4B. Regarding current trading prices, IMAB is priced at $2.88, while KNSA trades at $53.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas KNSA's P/E ratio is 58.62. In terms of profitability, IMAB's ROE is -0.09%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, IMAB is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check KNSA's competition here
IMAB vs NAMS Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, IMAB is priced at $2.88, while NAMS trades at $35.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas NAMS's P/E ratio is -18.94. In terms of profitability, IMAB's ROE is -0.09%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, IMAB is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check NAMS's competition here
IMAB vs TVTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, TVTX has a market cap of 3.9B. Regarding current trading prices, IMAB is priced at $2.88, while TVTX trades at $43.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas TVTX's P/E ratio is -84.52. In terms of profitability, IMAB's ROE is -0.09%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, IMAB is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check TVTX's competition here
IMAB vs CPRX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, IMAB is priced at $2.88, while CPRX trades at $31.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CPRX's P/E ratio is 18.04. In terms of profitability, IMAB's ROE is -0.09%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IMAB is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CPRX's competition here
IMAB vs RYZB Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IMAB is priced at $2.88, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IMAB's ROE is -0.09%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IMAB is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RYZB's competition here
IMAB vs CBAY Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IMAB is priced at $2.88, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IMAB's ROE is -0.09%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IMAB is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CBAY's competition here
IMAB vs CRNX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, IMAB is priced at $2.88, while CRNX trades at $36.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas CRNX's P/E ratio is -6.80. In terms of profitability, IMAB's ROE is -0.09%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IMAB is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CRNX's competition here
IMAB vs DNTH Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, IMAB is priced at $2.88, while DNTH trades at $88.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas DNTH's P/E ratio is -20.25. In terms of profitability, IMAB's ROE is -0.09%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, IMAB is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check DNTH's competition here
IMAB vs SWTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IMAB is priced at $2.88, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IMAB's ROE is -0.09%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, IMAB is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check SWTX's competition here
IMAB vs ACAD Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, IMAB is priced at $2.88, while ACAD trades at $20.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ACAD's P/E ratio is 9.27. In terms of profitability, IMAB's ROE is -0.09%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, IMAB is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ACAD's competition here
IMAB vs TLX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, TLX has a market cap of 3.4B. Regarding current trading prices, IMAB is priced at $2.88, while TLX trades at $10.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas TLX's P/E ratio is -508.50. In terms of profitability, IMAB's ROE is -0.09%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IMAB is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check TLX's competition here
IMAB vs EWTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, EWTX has a market cap of 3.4B. Regarding current trading prices, IMAB is priced at $2.88, while EWTX trades at $32.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas EWTX's P/E ratio is -18.93. In terms of profitability, IMAB's ROE is -0.09%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, IMAB is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check EWTX's competition here
IMAB vs VCYT Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, IMAB is priced at $2.88, while VCYT trades at $44.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas VCYT's P/E ratio is 38.60. In terms of profitability, IMAB's ROE is -0.09%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, IMAB is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check VCYT's competition here
IMAB vs VKTX Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, VKTX has a market cap of 3.3B. Regarding current trading prices, IMAB is priced at $2.88, while VKTX trades at $29.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas VKTX's P/E ratio is -6.84. In terms of profitability, IMAB's ROE is -0.09%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, IMAB is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check VKTX's competition here
IMAB vs ERAS Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, ERAS has a market cap of 3.2B. Regarding current trading prices, IMAB is priced at $2.88, while ERAS trades at $11.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas ERAS's P/E ratio is -11.10. In terms of profitability, IMAB's ROE is -0.09%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, IMAB is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for IMAB.Check ERAS's competition here
IMAB vs DNLI Comparison May 2026
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 542M. In comparison, DNLI has a market cap of 2.9B. Regarding current trading prices, IMAB is priced at $2.88, while DNLI trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -5.65, whereas DNLI's P/E ratio is -6.29. In terms of profitability, IMAB's ROE is -0.09%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, IMAB is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check DNLI's competition here